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Abstract
The transcriptional regulator EVI1 has an essential role in early development and haematopoiesis. However, acute
myeloid leukaemia (AML) driven by aberrantly high EVI1 expression has very poor prognosis. To investigate the effects
of post-translational modifications on EVI1 function, we carried out a mass spectrometry (MS) analysis of EVI1 in AML
and detected dynamic phosphorylation at serine 436 (S436). Wild-type EVI1 (EVI1-WT) with S436 available for
phosphorylation, but not non-phosphorylatable EVI1-S436A, conferred haematopoietic progenitor cell self-renewal
and was associated with significantly higher organised transcriptional patterns. In silico modelling of EVI1-S436
phosphorylation showed reduced affinity to CtBP1, and CtBP1 showed reduced interaction with EVI1-WT compared
with EVI1-S436A. The motif harbouring S436 is a target of CDK2 and CDK3 kinases, which interacted with EVI1-WT. The
methyltransferase DNMT3A bound preferentially to EVI1-WT compared with EVI1-S436A, and a hypomethylated cell
population associated by EVI1-WT expression in murine haematopoietic progenitors is not maintained with EVI1-
S436A. These data point to EVI1-S436 phosphorylation directing functional protein interactions for haematopoietic
self-renewal. Targeting EVI1-S436 phosphorylation may be of therapeutic benefit when treating EVI1-driven leukaemia.
Introduction
EVI1 is a transcriptional regulator with essential func-
tions in early haematopoiesis and development1,2. Aber-
rantly high expression of EVI1, often caused by
chromosomal rearrangements involving the MECOM
(MDS-EVI1 complex) locus at 3q26, where EVI1 is
encoded, is highly oncogenic. Acute myeloid leukaemia
(AML) with high EVI1 expression is one of the most
aggressive forms of AML with poor outcome3,4. How
overexpressed EVI1 drives transformation to chemo-
resistant leukaemia is incompletely understood. Several
protein isoforms are transcribed from the MECOM locus,
of which the 1051 amino acid (aa) EVI1 isoform confers
most oncogenic properties when aberrantly expressed at
high level5,6. This EVI1 isoform consists of an N-terminal
zinc finger domain with seven motifs, a proline-rich
central repressor domain, a smaller C-terminal zinc finger
domain with three motifs, and a carboxy-terminal acidic
domain (Fig. 1a). A longer MDS-EVI1 isoform, which has
an additional N-terminal PR domain with methyl-
transferase activity, supports normal haematopoietic self-
renewal, and can be expressed alongside the other EVI1-
isoforms7. The shorter ΔEVI1 isoform, which lacks 342 aa
(190–514) including the seventh zinc finger of the N-
terminal zinc finger domain, is ordinarily co-expressed
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with EVI1 (Fig. 1a). ΔEVI1 does not sustain normal
development in mice and cannot transform Rat-1 fibro-
blasts8,9. This implies an essential function of the
sequence outspliced in ΔEVI1. Clinical detection of the
heterozygous mutation c.1302_1306del in this region in
an infant with bone marrow failure further supports its
essential role in normal haematopoiesis10. EVI1 mod-
ulates gene expression by direct binding to specific DNA
sequences11,12, and engages in dynamic interactions with
other transcriptionally active proteins and epigenetic
regulators6,13,14. EVI1 interactions are in part governed by
post-translational modifications13,15. To further under-
stand the role of individual sites of EVI1 phosphorylation
we have analysed endogenously expressed EVI1 from
AML cells. We report here on the phosphorylation at
EVI1 serine 436 (S436), which is located in a functionally
essential region of EVI1. We provide evidence and
mechanistic insights for a role of this phosphorylation in
EVI1-mediated haematopoietic self-renewal.
Materials and methods
Cell lines and tissue culture
The EVI1 expressing AML cell line SB1690CB, the
EVI1-negative AML cell line OCI-AML5, HEK293T cells
and Rat-1 fibroblasts were cultured as previously descri-
bed15,16. All cell lines were regularly authenticated by STR
profiling and were mycoplasma free. Murine haemato-
poietic progenitor cells were isolated, purified and main-
tained as described previously15. For further details, see
Supplementary Materials and Methods.
Antibodies
For detection and immunoprecipitation of human EVI1
a polyclonal antibody raised against the N-terminal EVI1
epitope MKSEDYPHETMAPDI (Eurogentec, Seraing,
Belgium), and the EVI1 antibodies #2265 and #2593 (Cell
Signaling Technology (CST), Leiden, The Netherlands)
were used. For other antibodies, see Supplementary
Materials and Methods, Supplementary Table 1.
Fig. 1 EVI1 is phosphorylated at S436. a Schematic illustration of the EVI1 and ΔEVI1-protein isoforms showing DNA binding zinc finger domains
(ZF) and CtBP-binding motifs (CtBP). S436 phosphorylation shown in a red circle, in relation to the EVI1-SPLQ motif EVI1 with other species and the
putative nuclear localization signal (NLS). Immunoprecipitation of endogenously expressed EVI1 is from SB1690CB cells shown in the western blot of
EVI1. b, c Mass spectrometry analysis of the EVI1 peptide Asp433-Lys447 from SB1690CB AML cells non-phosphorylated (b) and S436-phosphorylated
peptides (c).
Paredes et al. Cell Death and Disease          (2020) 11:878 Page 2 of 14
Official journal of the Cell Death Differentiation Association
Immunoprecipitation, co-immunoprecipitation and
western blot analysis
Cell lysis and immunoprecipitation were carried out as
previously described15,16. EVI1 was immunoprecipitated
with EVI1 antibody #2593 (CST) and captured with
protein A sepharose beads. For immunoprecipitation of
flag-tagged proteins transfected cells were incubated for
one hour with FlagM2 magnetic beads (Sigma, Darmstadt,
Germany). Protein electrophoresis and western blots were
carried out using standard methodologies. For western
blot quantification see Supplementary Materials and
Methods.
Plasmids and site-directed mutagenesis
The human EVI1 coding region was excised from
pBABE-puro-flag-EVI1 (gift from Aubrey Thompson)
using SalI and EcoRI restriction sites and inserted into the
SalI and EcoRI sites of pCMV-flag-5a. Substitution of
S436 with alanine (A) to create the vector pCMV-EVI1-
S436A-flag was done by site-directed mutagenesis using
the QuikChange® II XL Kit (Agilent, Cheadle, UK). The
lentiviral vector expressing codon-optimized mouse Evi1-
pRRL.PPT.SF.EVI1mCo.IRES_EGFP.pre was mutated as
above to generate pRRL.PPT.SF.EVI1mCoS436.IRE-
S_EGFP.pre15,17–19. Control pRRL.PPT.SF.IRES_EGFP.
pre was generated by excision of the Evi1-ORF from
pRRL.PPT.SF.Evi1mCo.IRES_EGFP.pre vector with
BamHI restriction enzyme and religated to create an
empty backbone vector. Lentiviral packaging vectors
pHCMV-G, pMDLg/pRRE and pRSV-Rev were used as
described. Primer sequences are provided in the Supple-
mentary Material Table 2. Confirmation of mutated
sequence is illustrated in Supplementary Fig. 1. Tagged
DNMT3A was expressed using the cDNA-HA-DNMT3A
plasmid encoding HA-tagged DNMT3A20.
Reporter gene analysis
Reporter gene assays were carried out as described
before15 (details in Supplementary Materials and Meth-
ods) with western-blot-monitored EVI1 expression (Sup-
plementary Fig. 1b).
Serial replating of haematopoietic progenitors
Murine haematopoietic c-Kit+ stem and progenitor
cells (KIT+ HSPCs) were isolated from bone marrow of
8–10-week-old C57/BL6 mice as previously described15.
Lentiviral-mediated transduction was carried out with the
EVI1 vectors pRRL.PPT.SF.EVI1mCo.IRES_EGFP.pre,
and site mutated pRRL.PPT.SF.EVI1mCoS436.IRE-
S_EGFP.pre as described. In brief, cells cultured in med-
ium supplemented with 4 μg/mL protamine (Sigma) were
sequentially infected with two viral batches by spinocu-
lation (60 min at 1250 × g at 32 °C), and cultured for two
days in prestimulation serum-free cytokine supplemented
medium (StemCell Technologies, Cambridge, UK), prior
to FACS selection of GFP+ cells. Equal transduction
efficiency for Evi1-WT and Evi1-S436A was monitored by
RT-PCR and quantitation of fluorescent signal (Supple-
mentary Fig. 1). For replating 2 × 104 GFP+ cells were
plated in cytokine supplemented Methocult M3231
medium. After 7 days in culture, colonies were counted
and morphologically assessed. Cells were then harvested,
and 2 × 104 cells were replated as before. Colonies were
scored for subsequent rounds of replating as above. For
morphological analysis cytospin preparations were stained
with May–Grünwald Giemsa (Supplementary Fig. 1), and
200 cells per preparation were assessed.
Immunofluorescence (IF)
For immunofluorescence cells were incubated with
antibodies following standard procedures and image
generation (further details in Supplementary Materials
and Methods).
Co-localisation of EVI1 and 5mC signals was assessed
by determination of Pearson correlation coefficient ran-
ging from +1 (maximal correlation) to −1 (maximal anti-
correlation). r and p values were calculated using the free
source Social Science Statistics.
Gene expression analysis
For Poly-A RNA sequencing (RNAseq) analysis of Evi1-
mediated modulation of gene expression RNA was
extracted from murine haematopoietic c-Kit+ stem and
progenitor cells (KIT+ HSPCs) at 48 h after lentiviral
transduction with Evi1-WT, Evi1-S436A or vector-only,
and untransduced cells using the RNA/DNA Purification
Micro Kit (Norgen Biotek Corp, Thorold, Ontario,
Canada). Libraries were prepared with the Lexogen
QuantSeq 3’ mRNA-Seq Library Prep Kit for Illumina
(FWD) using an input of 200 ng and performing 14 cycles
of amplification. Indexed libraries were then quantified
using the Kapa Illumina Library quantification kit (Cat
07960336001) and pooled. 1 × 75 bp sequence reads were
generated by clustering 2.0 pM of the library pool on a
NextSeq500 High throughput run. Ordered BAM files
were generated against the mouse genome feature file
Homo_sapiens.GRCh38.90.gtf downloaded from Ensembl
(ftp://ftp.ensembl.org/pub/current_gtf). Data analysis was
performed using Qlucore Omics Explorer 3.3 (Qlucore,
Lund, Sweden) with a FPKM (Fragments Per Kilobase
Million) cut-off of 10. We used Deseq2, which converts
read counts to a normalised value based using size factors
to normalise for differences in the depth of sequence
between samples (geometric size factor normalisation
method) to calculate fold changes. To capture similarities
of changes mediated by Evi1-WT and Evi1-S436A trans-
duction, data analysis was carried out by applying a false
discovery rate (FDR)-modified (p < 0.05) pair comparison
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of Evi1-WT vs vector control and Evi1-S436A vs vector
control. We applied a group ANOVA for differences in
median expression between Evi1-WT and Evi1 S436A and
vector-only transduced cells with a p-value range of 2.3 ×
10−8 to 0.01. In order to determine the connectivity of
differentially regulated genes within the whole tran-
scriptome of Evi1-WT and Evi1-S436A mutant cells,
hypernetworks were used, which allow compression of
high dimensional relationships. Manhattan distance
matrices were generated for Evi1-WT and Evi1-S436A
transduced cells between all transcripts in each tran-
scriptome. Manhattan distances were preferred over
Euclidean distances as the former performs better in high
dimensions21. Selecting only the genes identified as
exclusively and significantly regulated in each group, a
matrix, M, was generated, which described the relation-
ship between differentially expressed genes (nWT= 78,
nS436A= 106) and all other genes (nTotal= 23766). This
matrix was binarised using a threshold of the 30th centile,
so that only the closest relationships (smallest Manhattan
distances) were retained. Multiplication of matrix M by
the transpose of this matrix MT results in a square
hypernetwork matrix M ×MT whose values represent the
number of binary relationships shared between a pair of
genes. Connectivity was defined as the mean value for
each hypernetwork. To assess organisation of the con-
nections in these networks, entropy was calculated per
gene in each hypernetwork. In order to test whether
connectivity of each set of genes was greater than
expected by random chance, a randomized iterative
approach was used. Hypernetworks were generated 1000
times in each cell type, using a randomly selected set of
genes (nWT= 78, nS436A= 106) each time, and con-
nectivity and entropy were calculated.
Mass spectrometry (MS)
For MS analysis, EVI1 was immunoprecipitated from
6 × 108 SB1690CB AML cells. Following gel electrophor-
esis, EVI1 containing bands were excised and trypsin-
digested. Peptides were separated by liquid chromato-
graphy prior to electrospray mass spectrometry on a 4000
Q-TRAP mass spectrometer (AB Sciex, Warrington, UK).
MS/MS data were interrogated using MASCOT and
confirmed by manual inspection of spectra. Interactome
analysis was carried out on in-gel digested samples of
EVI1-immunoprecipitate Flag-IP of Flag-tagged EVI1-
WT or EVI1-S436A transfected HEK293 cells using
standard methodologies (Supplementary Material and
Methods).
In silico analysis of kinase prediction and protein
modelling
Kinase prediction: Kinase prediction for EVI1 S436
phosphorylation was carried out using the PHOSHONET
platform22. Protein modelling: To model the structure of
the 426-598aa region of EVI1 the Iterative Threading
ASSEmbly Refinement (I-TASSER) was used (https://
zhanglab.ccmb.med.umich.edu/I-TASSER/)23. Five struc-
tures were predicted for EVI1 and assessed by C- and
TM-score (confidence scores for estimating the quality of
predicted models by I-TASSER). The model prediction
with maximum C-score (−0.94) and TM-scores (0.60 ±
0.14) was selected, quantifying the accuracy of the model
built. The EVI1-CtBP1 interaction was simulated through
modelling of protein-protein docking using ClusProserver
applying the initial coordinates of the structure of CtBP1,
(28–378), which has largely been resolved
(PDB:6CDR)24,25. Proteins were in silico positioned in a
cubic periodic box with each side at least 1 nm away from
the protein. The complexes were parameterized using
GROMOS 54A7 force field in a cubic box solvated with
SPC water model26,27. Both CtBP-binding motifs were
used when setting attraction in the docking parameters in
ClusPro. In order to examine the phosphorylation at S436
of EVI1, the ViennaPTM tool was used to modify EVI1-
CtBP1 PDB file and obtain force-field parameters for
phosphorylated EVI1-CtBP128. A neutral charge was
introduced at 150 mM NaCl. Long-range interactions
were defined using the particle mesh Ewald (PME) algo-
rithm29. Energy minimization was carried out using
steepest descent after applying position restraints to heavy
atoms. This was followed by a 100 ps NVT ensemble at
300 K, and a100ps NPT ensemble at 300 K and 1 bar30,31.
Production MD was performed at 300 K and 1 bar for
400 ns with frames written every 2 pico seconds. GRO-
MACS modules, such as gmx rms, gmx rmsf and gmx
energy, were used to analyse the stability and behaviour of
each system32–34. Root Mean Square Fluctuation (RMSF)
was calculated for of Cα atoms coordinates of EVI1 in the
EVI1-CtBP1 complex, and the p(S436) EVI1-CtBP1
complex in the last 350 ns to ensure the complex
reached equilibrium. The g_mmpbsa tool was used to
calculate the binding free energy of EVI1-CtBP1 complex
and the contribution of S436 to the binding energy by
means of energy decomposition33. All molecular dynam-
ics (MD) work was generated through HighPerformance
Computing facility (Barklacluster, University of Liverpool)
using Gromacsv.5.1.429,32.
Results
Dynamic EVI1 phosphorylation at serine 436 (S436)
We analysed by mass spectrometry (MS) immunopre-
cipitated EVI1 from SB1690CB AML cells, which express
high levels of EVI1 and ΔEVI135 (Fig. 1a). We identified
the EVI1 peptide DKVSPLQNLASINNK (aa 433–447)
(NCBI accession: NP_001098548.2), unmodified (Fig. 1b),
and in a phosphorylated form at serine S436 (Fig. 1c), in
addition to the previously reported EVI1 phosphorylation
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sites S196, S858 and S86015,16. This confirmed EVI1-S436
phosphorylation listed in other studies of cell lines and
clinical samples13,36. The presence of EVI1-peptides, both
phosphorylated, and unmodified at S436, implies a
dynamic process involving the region of EVI1 situated
adjacent to a putative nuclear localization site (NLS,
KEKFKENGKMFKDK aa 421–434), and close to the two
CtBP-binding domains of EVI1 (PFDLT aa 553–559, and
PLDLS aa 584–590) (Fig. 1a).
S436 available for phosphorylation is required for EVI1-
mediated haematopoietic self-renewal
To study the role of phospho-S436 EVI1 we first gen-
erated a non-phosphorylatable version of EVI1: EVI1-
S436A (Supplementary Fig. 1). To confirm minimal effect
of the EVI1-S436A mutation predicted in silico by Pre-
dictProtein37, we compared its localization, PLZF and
FOZ promotor repression, and Rat-1 fibroblast transfor-
mation with EVI1-WT as previously described (Supple-
mentary Methods)15. We observed no differences in all
the above functional readouts (Supplementary Fig. 1d–j).
By contrast, in serial replating assays of murine haema-
topoietic c-Kit+ stem and progenitor cells (KIT+ HSPCs),
EVI1-WT was significantly more efficient in sustaining
proliferation and preventing differentiation of blast cells
than EVI1-S436A (Fig. 2a, b) with equivalent levels of
retroviral transduction and EVI1 expression (Supple-
mentary Fig. 2). Expression of EVI1-WT led to sustained
clonogenic activity of KIT+ HSPCs by comparison with
untransduced or empty vector transduced cells over three
rounds, as previously shown15,16,18. However, by com-
parison with EVI1-WT expressing cells, there were sig-
nificantly fewer EVI1- S436A expressing colonies beyond
round two, suggesting an essential function for EVI1-S436
site available for phosphorylation in sustaining EVI1-
mediated self-renewal of murine KIT+ HSPCs (Fig. 2a, b).
Reflecting this, EVI1-WT expression conferred a higher
frequency and persistence of blasts from round two
onwards. Conversely, EVI1-S436A transduced cells
exhibited substantially higher levels differentiated cells
with an increased macrophage count (Fig. 2c, d, and
Supplementary Fig. 2f).
Phosphorylatable S436 EVI1 directs transcriptional
changes associated with self-renewal
To investigate the effect of phosphorylatable S436 on
the transcriptome, we expressed EVI1-WT and EVI1-
S436A in KIT+ HSPCs for 48 h and compared the effects
of transcriptional patterns by RNA sequencing (RNAseq)
(Fig. 3a). Vector-only transduced and untransduced con-
trol cells in biological triplicates were also analysed
(Supplementary Excel Table 1). Unsupervised principal
component analysis of gene expression patterns showed
tight clustering of replicates for EVI1-S436A transfected
samples, while in concordance with availability of S436 for
phosphorylation EVI1-WT-transduced replicates clus-
tered with a wider distribution and partial overlap with
EVI1-S436A (Supplementary Fig. 3a). We first captured
common transcriptional changes mediated by EVI1-WT
and EVI1-S436A quantitatively and performed a group
comparison between EVI1-WT and vector-only trans-
duced cells. We found 653 genes significantly changing,
497 upregulated and 156 downregulated applying a cut-
off log-fold change (FC) of >0.6 and a false discovery rate
(FDR)-adjusted p-value of <0.05 (Fig. 3b, Supplementary
Excel Table 1, sheet 2). Amongst these were known EVI1-
regulated genes such as the stem cell marker Aldha1a,
and more than half of the top 40 upregulated genes
identified in a previous study investigating the effect on
Evi1-transduction on murine haematopoietic pre-
cursors18. In this group Cepba was also downregulated,
previously shown to be repressed by Evi1-mediated
interference in myeloid maturation38 (Fig. 3c). Comparing
EVI1-S436A with vector-only controls, expression of 816
genes changed significantly (567 upregulated, 249 down-
regulated) (Fig. 3b). Strikingly, 444 of these genes changed
concordantly with EVI1-WT, including Aldh1a1 (Fig. 3b,
c, Supplementary Excel Table 1, sheet 2). Among 372
genes changing significantly exclusively with EVI1-S436A
we identified upregulation of Spi1, which is involved with
Evi1-driven myeloid haematopoietic skewing39, and
downregulation of Ms4a3, of which repression has pre-
viously been implicated in EVI1-mediated malignant
progression40. Also Gbp6, Nqo1 and Cdh17, which were
previously shown to be regulated by EVI1 in murine
progenitor cells18, were significantly changed exclusively
via the non-phosphorylatable Evi1-S436A. We noted that
many genes, including Spi1 and Ms4a3 showed con-
cordant changes both with EVI1-WT and EVI1-S436A,
albeit not reaching significance in one or the other group
(Fig. 3c), further illustrating a broad overlap of EVI1-WT
and EVI1-S436A mediated gene expression patterns after
48 h. In order to delineate expression patterns that sig-
nificantly discriminate Evi1-WT from Evi1-S436A trans-
duced cells, we next applied a group ANOVA test to the
dataset: 620 genes discriminated EVI1-WT, EVI1-S436A
and vector-only transduced cells with a p value range of
2.3 × 10−8 to <0.01 (Fig. 3e). Significantly and exclusively
modulated by EVI1-WT, were 78 genes. Of these, 64
genes were upregulated (Fig. 3e, green cluster, Supple-
mentary Excel Table 1, sheet 3), and 14 downregulated
(Fig. 3e, orange cluster). Significantly and exclusively
upregulated by EVI1-S436A were 19 genes (Fig. 3e, yellow
cluster), and repressed exclusively by Evi1-S436A were 87
genes (Fig. 3e, brown clusters). Comparing Evi1-WT (with
EVI1-436 available for phosphorylation) with Evi1-S436A
transduction, we can demonstrate that genes exclusively
and significantly regulated by EVI1-WT displayed a
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Fig. 2 EVI1 with S436 available for phosphorylation is required for EVI1-mediated haematopoietic self-renewal. a Schematic representation
of the replating assay of haematopoietic progenitors. Immunomagnetic sorted murine haematopoietic c-Kit+ stem and progenitor cells (KIT+ HSPCs)
cells were lentivirally transduced, GFP- FACS selected and plated. After 7 days, colonies were counted and cells harvested for replating (2nd round).
The procedure was repeated for a 3rd round. b Colony counting (n= 6, 6 different mice) after 1st round (left), 2nd round (middle) and 3rd round
(right). Statistical analysis: ordinary one-way ANOVA with Tukey post-test. Mean ± SD, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s.= non-significant).
c May–Grünwald Giemsa stain of cells from colonies after first, second and third rounds. Black arrowheads point at cells with typical blast
morphology. d Blast counts from the 1st, 2nd and 3rd round of replating. Statistical analysis: one-way ANOVA, Tukey posttest (mean ± SD, *p < 0.05;
***p < 0.001).
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Fig. 3 (See legend on next page.)
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significantly narrower diversity of connections than EVI1-
S436A (p < 2.2 × 10−16) (Fig. 3f, g). Moreover, a hyper-
network generated with the EVI1-S346A mutant
regulated patterns had significantly higher entropy than
EVI1-WT regulated (p < 2.2 × 10−16), demonstrating that
coordination of the higher connectivity between the genes
in S436A regulated patterns is low (Fig. 3h). It follows that
the effect on the entire transcriptome conferred by Evi1-
WT transduction, and mediating self-renewal, has a sig-
nificantly more coordinated and focussed effect than that
of non-phosphorylatable EVI1-S436. Hypernetwork con-
nectivity and entropy were greater with Evi1-S436A
transduction than in hypernetworks of the same size
generated from randomly selected genes iterated 1000
times (p < 2.2 × 10−16) (Supplementary Fig. 3b, c).
EVI1-S436 phosphorylation negatively affects interaction
with CtBP1
Given the location of S436 between the EVI1 zinc finger
motifs, and equal promotor affinity with respect to PLZF
and FOS repression with WT and S436A mutated EVI1,
we hypothesized that the S436 phosphorylation directs
gene expression patterns not by differential DNA binding,
but by interaction with other transcriptionally active
proteins. A role of S436 phosphorylation for protein
interactions was also considered, because S436 is in close
proximity to the EVI1-binding sites for the co-repressor
CtBP1, which has been shown to be essential for EVI1-
mediated haematopoietic self-renewal41–43 (Fig. 1). We
hypothesized that the S436 phosphorylation might med-
iate CtBP1 binding, as only EVI1-WT with S436 available
for phosphorylation conferred self-renewal. While the
tertiary structure of EVI1 is not fully resolved and there is
little homology of EVI1 with other proteins, the interac-
tion of EVI1 with CtBP1 has been studied in some
detail41–43. We therefore modelled the 172aa 426-598
region of EVI1. Cross species sequence alignment of the
sequence of the entire region reveals strong conservation
of S436 and both CtBP1-binding motifs, implying an
essential role for structure and function of EVI1 (Fig. 4a).
We next used Iterative-Threading Assembly Refinement
(I-TASSER) to model the structure with the highest
confidence score23. This predicted several α-helix for-
mations involving S436 and both CtBP1-binding sites
(Fig. 4a, b). As the crystal structure of CtBP1 has been
largely resolved24,44,45, we modelled the docking of the
predicted 172aa 426-598 structure of EVI1 with CtBP1
using ClusPro (Fig. 4c)25. We simulated the effect of S436
phosphorylation on the dynamics of the CtBP1-EVI1
interaction using Gromacs with 400 ns molecular
dynamics (MD)29,33,34. This predicted a stable α-helix
configuration within the CtBP1-binding site 553-557 (Fig.
4a) for the CtBP1 docking formation modelled with
residues 28–378 (Fig. 4a, b). However, EVI1 S436 phos-
phorylation is predicted to destabilise this α-helix for-
mation, which may potentially affect the interaction
between EVI1 and CtBP1 (Fig. 4d). We calculated the
effect of the binding affinity of the 172aa 426–589 region
of EVI1 using Molecular Mechanics-Poisson Bolzmann
Surface Area (MM-PBSA)33. Estimation of the binding
energy for the EVI1-CtBP1 complex shows that EVI1-
S436 phosphorylation unfavourably shifts the binding
energy by approximately 100 kJ/mol (ΔGbinding > 0) (Sup-
plementary Fig. 4a), mainly caused by the phosphate
group affecting the electrostatic energy. Unpho-
sphorylated EVI1 at S436 in the EVI1-CtBP1 complex
contributes favourably (ΔGbinding < 0) to the binding
energy (Supplementary Fig. 4b), but after phosphorylation
the mean contribution of S436 shifted unfavourably from
−2.9 KJ/mol to 19.47 KJ/mol. In summary, contrary to our
hypothesis, dynamic protein interaction modelling pre-
dicted a negative effect of S436 phosphorylation on the
affinity of EVI1 for CtBP1. To experimentally verify this
prediction, we quantitatively co-immunoprecipitated
CtBP1 with Flag-tagged EVI1-WT and EVI1-S436A. We
found a significantly increased association of non-
phosphorylatable EVI1-S436A with CtBP1, in line with
the in silico prediction (Fig. 4e, f). To exclude the possi-
bility that higher CtBP1 affinity of EVI1-S436A was
nonspecific, we also quantified the co-
immunoprecipitated AAA-ATPase RUVBL2 protein,
which also interacts with EVI113, and is functionally
(see figure on previous page)
Fig. 3 Gene expression is differentially modulated by EVI1-WT and EVI1-S436A. a Experimental design. Murine haematopoietic c-Kit+ stem and
progenitor cells (KIT+ HSPCs) cells were isolated and transduced with Evi1-WT and Evi-S436. 48 h after transduction RNA was extracted and processed
for RNAseq analysis. b Two-way RNAseq analysis of Evi1-WT vs vector-only and Evi1-S436A vs vector-only transduced KIT+ HSPCs. Venn diagram of
transcripts significantly changed by Evi1-WT or Evi1-S436A (adj. p > 0.05, FC > 0.6). c Heatmap illustration of selected differentially expressed genes in
the two-way comparison (black triangle: adj.p < 0.05) d Regression analysis comparing fold change of significantly (p < 0.05) changing transcripts in
Evi1-WT and Evi1-S436A transduced cells. e Heatmap illustration of group-ANOVA analysis of vector-only-, Evi1-WT - and Evi1-S436 transduced KIT+
HSPCs, adj. p value range of 2.3e−8 to <0.01. f, g Hypernetwork heatmap for Evi1-WT (n= 78 transcripts, mean connectivity= 2376) and Evi1-S436A
(n= 106 transcripts, mean connectivity= 3561), respectively. Colour intensity represents number of binary relationships shared between a pair of
transcripts with the rest of the transcriptome (n= 23766 total transcripts) h Shannon entropy in Evi1-WT (n= 78) and Evi1-S436A (n= 106) induced
hypernetworks (p < 2.2e−16).
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relevant for other leukaemogenic transcription fac-
tors46,47. We showed significantly higher affinity of
phosphorylatable EVI1-WT to RUVBL2 compared with
non-phosphorylatable EVI1-S436A (Fig. 4e, f).
Preferential association of EVI1-WT with target-specific
kinases and DNMT3A
To investigate more broadly the effect of phosphor-
ylatable S436 on EVI1-protein affinity and to determine
possible kinases involved, we expressed FLAG-tagged
EVI1-WT and EVI1-S436A in HEK293 cells and carried
out affinity purification by FLAG-IP and MS analysis
versus empty vector control. We considered another MS
study of MECOM-encoded proteins, in addition to pre-
viously described protein interactions for our data ana-
lysis6,13 (Supplementary Excel Table 2). In addition, we
carried out further analysis using the “CRAPome” plat-
form to consider nonspecific interactions48 (Supplemen-
tary Excel Table 2, sheet 2). With EVI1-WT and EVI1-
S436A we co-immunoprecipitated 926 and 702 proteins,
respectively. Of these, 263 proteins co-immunoprecipated
with both EVI1-WT and EVI1-S436A (Fig. 5a). The
number of detected proteins is similar to that in the
interactome study concerning MECOM-encoded proteins
in T47D breast cancer cells6, with which there is a con-
siderable overlap: 209 proteins in our dataset (22%) were
also detected in the Ivanochko study (Supplementary
Excel Table 2, sheet 3). Of these 209 proteins, 89 were
detected exclusively in the EVI1-WT interactome, 65 in
both IPs, and 55 exclusively in the EVI1-S436A inter-
actome. Of the previously described 102 proteins that
interact with EVI113 (Supplemental Excel Table 2, sheet
4), we identified 21 in our dataset, of which 17 were
detected exclusively in the EVI-WT IP, and three in both.
Only one previously described EVI1-interacting protein
(PRDX1) was detected exclusively with EVI1-S436A13.
Our data demonstrate that phosphorylatable EVI1-WT
interacts with more proteins and co-immunoprecipitates
with more known EVI1-interactors than EVI1-S436A,
supporting the concept that EVI1-S436 phosphorylation
serves to facilitate protein recruitment for functional
interactions.
Several kinases were identified in the EVI1-WT inter-
actome. An in silico analysis of the DKVSPLQNLASINNK
sequence of EVI1, using PhosphoNet22 showed that EVI1-
S436 is set in a protein sequence that is a putative target of
multiple kinases (Supplementary Fig. 5), including CDK2
and CDK3. Both CDK2 and CDK3 were detected in the
EVI1-WT interactome. We also detected the casein
kinase CSNK2A1, which has previously been implicated
in EVI1 phosphorylation13. Only a few of the proteins that
co-immunoprecipitated with EVI1 have been investigated
functionally for potential biological relevance, and for
most, a role in haematopoietic self-renewal is elusive.
However, in the EVI1-WT, but not in the EVI1-S436A
interactome, we detected the DNA methyltransferase
DNMT3A. DNMT3A has an essential role in haemato-
poiesis, interacts with EVI149,50, and has been suggested
to mediate EVI1-directed methylation patterns in AML20.
To confirm this MS finding, we transfected HEK293 cells
with HA-tagged DNMT3A together with EVI1-WT or
EVI1-S436A. Quantitative co-immunoprecipitation of
EVI1 and DNMT3A demonstrated a higher affinity of
EVI1-WT with DNMT3A compared with EVI1-S436A
(Fig. 5b, c), corroborating the MS findings.
S436 available for phosphorylation is required for EVI1-
mediated DNA-methylation patterns
The methyltransferase DNMT3A is an important
mediator of de novo cytosine DNA methylation in hae-
matopoietic self-renewal and differentiation. Loss of
DNMT3A function in haematopoietic progenitor cells
impairs differentiation and promotes self-renewal49.
Acquired mutations in DNMT3A, which prevent the
formation of catalytically active DNMT3A tetramers51,
are common in AML. In non-leukaemic haematopoietic
progenitors with inherited DNMT3A disruption focal
hypomethylation is a distinctive feature, while CpG-island
(see figure on previous page)
Fig. 4 Modelling of EVI1-S436 phosphorylation on CtBP1 affinity. a Alignment for the full-length amino acid sequences of EVI1 in Homo sapiens
(Uniport Q03112), Mus musculus (Uniport P14404), Rattus norvegicus (Uniport D3ZM26), Danio rerio (Uni- port F1Q834), Gallus gallus (Uniport
A0A3Q2U4Z4), Pan troglodytes (Uniport A0A2I3RS65) and Bos taurus (Uniport A0A3Q1LI16) were aligned using MUSCLE and visualized by ESPript
and aligned. b Three-dimensional prediction of the I-TASSER generated structure of the EVI1 region as in a. Both CtBP-binding motifs (blue) and the
S436 site are part of predicted α-helix structures. Hydrogen bonds formed by Ser436 with Gln440, Gln439 and Asp433 residues (dashed lines). c
I-TASSER-generated model of EVI1(aa426-598) for modelling the interaction between EVI1 and CtBP1 using ClusPro server. Both CtBP-binding motifs
were used when setting attraction in the docking parameters in ClusPro. d Modification of the complex according to the force-field parameters of
GROMOS 54A7 for effect of EVI1-S436 phosphorylation. Molecular dynamics simulations (400 ns) for modelling EVI1 complexation with CtBP1. Root
mean square fluctuation (RMSF) plot of Cα atoms of EVI1 in EVI1-CtBP1 complex and phospho(S436) EVI1-CtBP1 complex. Yellow: region of
EVI1 structure (553-566) affecting the α-helix stability containing the CtBP1-binding motif 1 (553-557). e Experimental confirmation: HEK293 cells
transfected with flag-tagged Evi1-WT or Evi1-S436A; protein extracts were subjected to Flag-magnetic beads immunoprecipitation to quantify EVI1-
CtBP1 co-Immunoprecipitation. Quantitation of immunoprecipitated RUVBL2 used as a control. f Quantitation of independent Co-IP assays (mean ±
SD, n= 3, unpaired, two-tailed Student’s t-test *p < 0.05) as shown in e.
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hypermethylation in AML is a consequence of leukaemic
progression52. We demonstrated distinct 5-mC staining in
untransduced KIT+ HSPCs in most cells with speckled
signal as previously described53 (Supplementary Fig. 6).
As DNMT3A preferentially interacts with EVI1-WT
compared with EVI1-S436A, we investigated if Evi1-WT
or Evi1-S436A transduction affects the 5-mC staining
patterns. With Evi1-WT transduction, but not with Evi1-
S436A, we noted a distinct population of entirely 5-mC-
negative cells (Fig. 6a). To quantify this observation, we
correlated the signal distribution of 5-mC- with the
EVI1 signal in Evi1-WT and Evi1-S436A transduced
KIT+ HSPCs. In Evi1-WT transduced cells the signal was
not correlated with the 5-mC staining (r= 0.0379) (Fig.
6b, e), caused by the distinct cell population with high
EVI1 signal, but low or absent 5-mC (Fig. 6c, d). The
absence of this cell population in Evi1-S436A transduced
cells resulted in a significantly higher correlation of the 5-
mC with the EVI1-S436A signal (Fig. 6b, f) (r= 0.517,
range −1 for total exclusion, 1 for total association).
Together, these results show that self-renewal mediated
by EVI1-WT is associated with maintenance of a cell
population with low 5-mC staining, which is absent in
EVI1-S436A.
Discussion
EVI1 and other MECOM-encoded transcriptional reg-
ulators are essential for early development and haemato-
poiesis, while aberrantly high expression of EVI1 has
potent oncogenic properties. Defining the role of EVI1 in
haematopoietic stem cell maintenance will also be
important for targeted therapeutic approaches for leu-
kaemia driven by high EVI1. There is accumulating evi-
dence for post-translational modifications governing EVI1
function, and phosphorylation is potentially ther-
apeutically targetable. Our MS analysis of endogenously
expressed EVI1 in SB1690CB AML cells confirmed S436
phosphorylation, which was previously listed in other
EVI1-overexpressing malignancies13,36. Presence of both
phosphorylated and non-phosphorylated S436 in leukae-
mia cells indicates a dynamic process, which involves a
region of the EVI1 protein that is spliced out in in the
Fig. 5 Protein association of EVI1-WT and EVI1-S436A. a Venn diagram showing the number of proteins associated with EVI1- WT (dark grey) or
EVI1-S436A analyzed by affinity purification and mass spectrometry of co-immunoprecipitated proteins. b Co-immunoprecipitation of Flag-tagged
EVI1-WT and EVI1-S436A, and HA-tagged DNMT3A in HEK293 cells and western blotting. c Signal quantitation of co-immunoprecipitated DNMT3A
(mean ± SD, n= 3, unpaired, two-tailed Student’s t-test; *p < 0.05).
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ΔEVI1 isoform. DNA binding sites of ΔEVI1 are largely
overlapping with EVI154, but ΔEVI1 does not transform,
or support normal development8,9. We show that the
non-phosphorylatable EVI1-S436 mutation, whilst main-
taining EVI1-functional readouts with respect to pro-
motor affinity, nuclear localisation and Rat-1
transformation, confers abrogated self-renewal capacity.
These data imply that the integrity of this region with the
S436 available for phosphorylation is essential for EVI1-
mediated haematopoietic self-renewal. Detailed analysis
of EVI1-WT and EVI1-S436A mediated expression pat-
terns in KIT+ HSPCs confirmed multiple EVI1 target
genes18, despite employment of a different experimental
setup, longer Evi1-exposure after transduction (48 vs
24 h) and another type of RNA analysis. Our analysis,
however, further delineates patterns of EVI1-modulated
transcriptional profiles, which are partly regulated inde-
pendently of S436 phosphorylation. Expression patterns
mediated by EVI1-WT include genes with an essential
role in stem cell maintenance, and show that EVI1 with
S436 available for phosphorylation has a much more
coordinated effect on the entire transcriptome, implying
that the S436 phosphorylation focuses transcriptional
patterns towards self-renewal. Recent data from our
group and others suggest that many EVI1 functions are
regulated by dynamic interactions with other pro-
teins6,13,15. To explain the differences in gene expression
patterns mediated by EVI1-WT compared with EVI1-
S436 we provide evidence for modulation of EVI1-protein
interactions by S436 phosphorylation, with increased
affinity of non-phosphorylatable EVI1-S436A to CtBP1.
With respect to the CtBP1 interaction our results were
partly generated using high-end computational modelling
approaches, for which we took advantage of the known
CtBP1 structure24,44,45, and available data with respect to
EVI1 and CtBP1 binding41. Similar approaches for the
detailed analysis of the interaction of EVI1 with other
proteins (e.g. RUVBL2 and DNMT3A, see below) would
be illuminating, but lacking exact information about these
proteins’ EVI1-binding sites, this is currently not possible
Fig. 6 S436 available for phosphorylation is required for EVI1-mediated DNA-methylation patterns. a Quantitation of total 5-mC+i in KIT+
HSPCs cells after transduction with Evi1-WT or Evi1-S436A. Cells were scored by presence of absence of 5-mC IF stain (one-way ANOVA, Tukey post-
test, mean ± SD, *p < 0.05, **p < 0.01). b Correlation of the EVI1 and 5-mC signals by Pearson’s test (r range −1 for total exclusion, 1 for total
association) for EVI1-WT (black circles) and EVI1-S436A (green circles). c Signal ratio of Evi1 and 5-mC (t-test; **p < 0.01). d Quantitation as in E of 3
independent experiments (mean ± SD, *p < 0.05). e, f Top panels illustrate individual stains (gray scale) of EVI1, DAPI and 5-mC, bottom panels
merged. Arrows indicate cells in corresponding upper and lower panels with high EVI1-WT signal and absent 5 mC signal (white), and cells with high
EVI1-S436A signal cells with high EVI1 signal and high 5 mC signal (orange).
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in the same way. The finding that EVI1-S436 phosphor-
ylation negatively affects affinity to CtBP1 was counter-
intuitive, as CtBP1 interaction is essential for EVI1
function, and only EVI1-WT with S436 available for
phosphorylation confers self-renewal. These data, toge-
ther with our previous observation concerning a mod-
ulation of CtBP1-association also via the carboxy-terminal
SQS-phosphorylation15, supports the concept of a
dynamic and kinase-governed complex and finely regu-
lated EVI1 interaction with CtBP1, and applies also to
other interactions, of which detailed understanding might
be therapeutically important for EVI1-overexpressing
malignancies. We investigated the RUVBL2 interaction
as a control for CtBP1, since this AAA-ATPase has been
shown to interact with EVI1 previously13, and is of
functional importance for other leukaemogenic tran-
scriptional regulators46,47. Preferential association of
EVI1-WT with RUVBL2 warrants further investigations
into the role of RUVBL2 for EVI1-mediated self-renewal.
Our MS-protein interaction studies implicate CDK2 and
CDK3 as likely kinases for S436 phosphorylation, as they
co-immunoprecipitated with EVI1-WT and share the
S436 target sequence. Selective and quantitative detection
of S436-phosphorylated and non-phosphorylated EVI1,
for example by a specific antibody and treatment with
selective CDK3 and other inhibitors would be necessary
for further investigations, particularly since as CDK3 has a
role for haematopoietic self-renewal in response to che-
motherapy55. Having demonstrated preferential interac-
tion of EVI1-WT with DNMT3A, we show that EVI1-WT
affects DNA-methylation patterns in haematopoietic
progenitor cells as assessed by 5-mC staining. Our data
with respect to the maintenance of a population with low
or absent 5-mC only by Evi1-WT suggests an interference
of EVI1 with de novo methylation. We are currently
further characterising the hypomethylated cell population
maintained by Evi1-WT transduction, and the genes
affected by differential methylation patterns, also in rela-
tion to differentially expressed transcripts in the RNAseq
analysis. We further investigate how the interaction with
aberrantly high levels of EVI1 affects tetramer assembly
and function of DNMT3A in normal haematopoietic
progenitor and transformed leukaemic cells, which also
might be relevant in the context of therapy with hypo-
methylating agents. Moreover, since the other MECOM-
encoded protein MDS-EVI1 (PRDM3) also contains the
S436 motif, investigations whether and how S436 phos-
phorylation affects the MDS-EVI1 protein are also
required. In summary, our data provide evidence of an
important role of EVI1-S436 and its availability for
phosphorylation for haematopoietic self-renewal via
modulation EVI1-protein interactions associated with
transcriptional changes, and alteration of EVI1-directed
DNA methylation. Aberrantly high expressed EVI1
appears to dynamically alter the composition and stoi-
chiometry of transcriptional regulatory complexes via its
S436 phosphorylation. Targeting the kinases promoting
S436 phosphorylation is worthy to investigate further for
therapeutic benefit in EVI1-driven leukaemia.
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